IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy

Brain Tumor Pathology

Volumn 30, Issue 2, 2013, Pages 67-72

  Motegi, Hiroaki ^a   Kamoshima, Yuuta ^a   Terasaka, Shunsuke ^a   Kobayashi, Hiroyuki ^a   Yamaguchi, Shigeru ^a   Tanino, Mishie ^a   Murata, Junichi ^b   Houkin, Kiyohiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sapporo Asabu Neurosurgical Hospital   (Japan)

Author keywords

Biomarker; Concurrent radiotherapy andtemozolomide; Glioblastoma; IDH1 mutation; Pseudoprogression

Indexed keywords

BIOLOGICAL MARKER; ISOCITRATE DEHYDROGENASE 1; TEMOZOLOMIDE; TUMOR MARKER; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DNA EXTRACTION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOME; GLIOBLASTOMA; HUMAN; IDH1 GENE; INCIDENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR PSEUDOPROGRESSION; WILD TYPE; ADULT; BRAIN TUMOR; CASE REPORT; DISEASE COURSE; FEMALE; GENETICS; MULTIMODALITY CANCER THERAPY; MULTIPLE CANCER; MUTATION; PATHOLOGY; RADIOTHERAPY; SECOND LOOK SURGERY;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; OLIGODENDROGLIOMA; RADIOTHERAPY; RETROSPECTIVE STUDIES; SECOND-LOOK SURGERY; TUMOR MARKERS, BIOLOGICAL;

EID: 84884215247     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-012-0109-x     Document Type: Article

References (17)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987- 996
2. Hygino da Cruz LC, Jr., Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978-1985
3. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
4. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996-1998
5. Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B (2012) Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 35:284-289
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
7. Hoffman WF, Levin VA, Wilson CB (1979) Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 50:624-628
8. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197
9. Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10:361-367
10. Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22:633-638
11. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H (2009) Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 72:423-428
12. Chamberlain MC (2008) Pseudoprogression in glioblastoma. J Clin Oncol 26:4359. author reply 4359-4360
13. Kang HC, Kim CY, Han JH, Choe GY, Kim JH, Kim IA (2011) Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. J Neurooncol 102:157-162
14. Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY, Park SH, Kim TM, Lee SH, Choi SH, Kim SK, Kim DG, Jung HW (2011) Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol 13:195-202
15. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63: 535-537
16. Wong CS, Van der Kogel AJ (2004) Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 4:273-284
17. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468:829-833